Data from Retrogenix’s IND-enabling specificity studies have been included in numerous regulatory applications. Our data is accepted globally; with submissions to the US FDA, EMA (Europe), PMDA (Japan) and NMPA (China).
Across the board, for all submissions that used Retrogenix data, the acceptance rate was 90% with 7% of the applications still in the process of submission.
How can our cell microarray platform advance therapeutic development?
Retrogenix’s unique cell microarray technology provides a fast, accurate solution for discovering the human cell surface and secreted protein targets of antibodies, proteins, CAR-T cells, viruses, and small molecules.
Our unique tool uses proprietary arrays of expression vectors – encoding over 6,200 human plasma membrane, tethered secreted, and heterodimer proteins – spotted onto slides. Human cells grown over the top become reverse-transfected, resulting in cell surface expression of each respective protein at distinct slide locations. The test molecule is applied and specific binding analysed and confirmed using an appropriate detection system.